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Activating CB1 cannabinoid receptor has been demonstrated to produce certain 
therapeutic effects in animal models of Alzheimer’s disease (AD). In this study, we 
evaluated the specific contribution of CB1 receptor to the progression of AD-like 
pathology in double transgenic APP/PS1 mice. A new mouse strain was generated by 
crossing APP/PS1 transgenic mice with CB1 knockout mice. Genetic deletion of CB1 
drastically reduced the survival of APP/PS1 mice. In spite that CB1 mutant mice bearing 
the APP/PS1 transgene developed normally, they suddenly died within the first two 
months of life likely due to spontaneous seizures. This increased mortality could be 
related to an imbalance in the excitatory/inhibitory transmission in the hippocampus as 
suggested by the reduced density of inhibitory parvalbumin positive neurons observed in 
APP/PS1 mice lacking CB1 receptor at 7 weeks of age. We also evaluated the AD-like 
phenotype of APP/PS1 mice heterozygous for the CB1 deletion at 3 and 6 months of age. 
The memory impairment associated to APP/PS1 transgene was accelerated in these mice. 
Neither the soluble levels of Aβ or the density of Aβ plaques were modified in APP/PS1 
mice heterozygous for CB1 deletion at any age. However, the reduction in CB1 receptor 
expression decreased the levels of PSD-95 protein in APP/PS1 mice, suggesting a 
synaptic dysfunction in these animals that could account for the acceleration of the 
memory impairment observed. In summary, our results suggest a crucial role for CB1 
receptor in the progression of AD-related pathological events.  
 







The Gi/o-coupled CB1 cannabinoid receptors are widely expressed within the central 
nervous system, in both neurons and glial cells. They are mostly located at the terminals 
of neurons where they act as modulators of excitatory and inhibitory neurotransmission, 
regulating important brain functions including cognition (Howlett, 2005). Moreover, CB1 
activity mediates protection against excitotoxicity and the induction of repair mechanisms 
in response to neuronal damage (Marsicano et al, 2003; Fagan and Campbell, 2014). 
Based on the neuroprotective properties of CB1 receptor activation, a number of studies 
have explored the role of this receptor in several neurodegenerative diseases, including 
Alzheimer’s disease (AD). AD is the most common form of dementia, histologically 
characterized by the dysfunctional accumulation of amyloid-β peptide (Aβ) and tau 
hyper-phosphorylation in major brain regions contributing to memory and cognition 
(Ferrer, 2012; Selkoe, 2012). Alterations in the expression or functionality of CB1 
receptors have been described both in AD patients’ brains (Ramírez et al, 2005; Solas et 
al, 2013; Manuel et al, 2014) and AD animal models (Kalifa et al, 2011; Aso et al, 2012a). 
Interestingly, a similar reduction in CB1 levels was observed in both human and animal 
models brains at advanced stages of the AD, in contrast with the increase in CB1 
expression during the asymptomatic stages (Aso et al, 2012a; Manuel et al, 2014). These 
findings suggest an attempt of CB1 receptor to compensate for the initial synaptic 
impairment occurring at the early asymptomatic stages of AD and reinforce the 
hypothesis that targeting the CB1 receptor could offer a strategy against AD. In fact, 
pharmacological stimulation of CB1 receptors with natural or synthetic agonists resulted 
in a reduction of the neurotoxic effect of amyloid-ß peptide (Aß) in some in vitro models 
(Noonan et al, 2010; Chen et al, 2011a; Aso et al, 2012a; Janefjord et al, 2014) and in a 




2012a; Haghani et al, 2012; Aso et al, 2015). The alleviation of the AD-like symptoms in 
these models seems not to be directly related to a significant contribution of CB1 receptors 
in Aβ production, aggregation or clearance since no modifications in such parameters 
were reported in two different transgenic AD models after chronic treatment with specific 
CB1 agonists (Aso et al, 2012a; Chen et al, 2010). However, a role for CB1 receptor on 
APP processing cannot be completely ruled out because APP23 transgenic mice deficient 
for CB1 receptor exhibited reduced APP protein levels and Aβ plaque deposition, likely 
due to changes in intracellular APP transport, although those animals presented enhanced 
cognitive deficits (Stumm et al, 2013).  
Considering these evidence, the aim of the present study was to further explore the 
specific contribution of CB1 receptor to the progression of AD in APP/PS1 transgenic 
mice deficient for CB1 receptor. We have chosen this animal model of AD because it 
reproduces some of the most relevant features of the disease, including cognitive 
impairment and Aβ plaques from the age of six months onwards (Borchelt et al, 1997; 
Aso et al, 2012b). Aβ deposition is accompanied in APP/PS1 mice by altered 
mitochondria and increased oxidative damage, post-translational modifications and 
accumulation of altered proteins at the dystrophic neurites surrounding plaques, likely 
due to aberrant degradation pathways (Aso et al, 2012b). However, cognitive decline in 
this AD model is assumed to correlate with the levels of soluble oligomeric species, which 
are known to play a critical role in the AD pathogenicity (Walsh and Selkoe, 2004). Thus, 
we have performed a time-course evaluation of the aberrant Aβ production and memory 




2. Materials and methods 
2.1. Animals 
Double transgenic APP(swe)/PS1(1dE9) (APP/PS1) mice are used in the present study 
as a model of familial AD because they reproduce some of the most relevant features of 
the disease, including cognitive impairment and several pathological alterations such as 
Aβ plaques, dystrophic neurites around Aβ deposition, and synaptic abnormalities from 
the age of six months onwards (Borchelt et al, 1997; Aso et al, 2012b). A new mouse 
strain was generated by crossing male APP/PS1 mice purchased from Jackson 
Laboratories (Bar Harbor, Maine, USA) with female CB1 knockout (-/-) mice (Zimmer 
et al, 1999) obtained from the European Mutant Mouse Archive (Helmholtz Zentrum, 
München, Germany), both strains in a C57BL/6 background. The resulting APP/PS1/CB1 
heterozygous (+/-) males were then crossed with wild-type (WT)/CB1 +/- females to 
obtain the animals for the present study. The genotype of the pups was analyzed with the 
polymerase chain reaction (PCR) technique using genomic DNA isolated from tail clips 
obtained at postnatal day 21 or at embryonic day 13.5. Animals were maintained under 
standard animal housing conditions in a 12-h dark-light cycle with free access to food 
and water. The experiments were conducted by experienced researchers blind for the 
genotype of the animals. All animal procedures were carried out following the guidelines 
of the European Communities Council Directive 2010/63/EU and with the approval of 
the local ethical committee of the University of Barcelona.  
2.2. Behavioral evaluation of cognitive performance: Two-object recognition test  
Memory performance was evaluated in WT/CB1 +/+, WT/CB1 +/-, WT/CB1 -/-, 
APP/PS1/CB1 +/+ and APP/PS1/CB1 +/- male littermates aged 3 and 6 months. On day 
1, mice were placed for 9 min in a V-maze where two identical objects were situated at 




four hours after the training session, animals were placed again in the V-maze where one 
of the two familiar objects was replaced by a novel object. The time that the animals spent 
exploring the two objects was recorded. Object recognition index (RI) was calculated as 
the difference between the time spent exploring the novel (TN) and the familiar object 
(TF) divided by the total time spent exploring the two objects [RI=(TN-TF)/(TN+TF)]. 
Animals exhibiting memory impairments showed a lower RI.  
2.3. Brain samples collection 
At the end of the behavioral testing, animals ageing 3 and 6 months were killed and their 
brains rapidly removed from the skull and processed for study. A group of mice, 
including APP/PS1/CB1 -/-, were sacrificed at 7 weeks of age for brain samples 
collection. One hemisphere was dissected on ice, immediately frozen, and stored at -80ºC 
until use. The other hemisphere was fixed in 4% paraformaldehyde and processed for 
immunohistochemistry.  
2.4. Immunohistochemistry 
Fixed tissue samples were embedded in paraffin, and coronal sections, 4 m thick, were 
cut with a microtome. Consecutive de-waxed sections were incubated with 98% formic 
acid (Aβ, 3 min) and then treated with citrate buffer (Aβ, parvalbumin, NeuN, 20 min) to 
enhance antigenicity. Then endogenous peroxidases were blocked by incubation in 10% 
methanol-1% H2O2 solution (15 min). Sections were blocked with 3% normal horse 
serum solution and then incubated at 4ºC overnight with the primary antibodies against 
Aβ (clone 6F/3D 1:50, Dako, Glostrup, Denmark), parvalbumin (PV, 1:1,000, Sigma-
Aldrich, St Louis, MO, USA) or the neuronal marker NeuN (1:100, Millipore, Burlington, 
MA, USA). Sections were subsequently rinsed and incubated with biotinylated secondary 
antibodies (Dako). Peroxidase reaction was visualized with diaminobenzidine and H2O2. 




dehydrated and cover-slipped for observation under a Nikon Eclipse E800 microscope 
(Nikon Imaging Inc., Tokyo, Japan). The cortical total Aβ burden was calculated as the 
percentage of the area of amyloid deposition in plaques with respect to the total cortical 
area (0.6 mm2) in 9 pictures taken from 3 different sections (-0.1 mm, -1.5 mm and -2.0 
mm from bregma, approximately) of the each animal brain (3 pictures per section 
corresponding to cingular/retrospenial and motor cortex, somatosensory cortex and 
piriform/entorrhinal cortex), corresponding to the main regions where Aβ deposition is 
observed in APP/PS1 mice. Density of PV+ and NeuN+ cells in hippocampus of each 
animal brain was calculated by counting the number of immunostained cells from 3 
different sections (-1.5 mm, -1.7 mm and -1.9 mm from bregma, approximately) with 
respect the total hippocampal area in the section (mm2). Quantifications were performed 
by a researcher blind for the corresponding genotype of each section. Aβ quantification 
and hippocampal area were calculated using the Analysis tool of the Adobe® Photoshop® 
CS4 software (Adobe Systems Inc., San Jose, CA, USA). The number of APP/PS1 mice 
analyzed for each genotype (CB1 +/+ and CB1 +/- or CB1 -/-) and age (<2, 3 or 6 months) 
was n = 5-10.  
2.5. Aβ soluble quantification: enzyme-linked immunosorbent assay (ELISA) 
Fresh-frozen mouse brain cortex was homogenized in 4 volumes (wt:vol) of TBS 
extraction buffer (140 mM NaCl, 3 mM KCl, 25 mM Tris (pH 7.4), 5 mM EDTA, and 
protease inhibitor cocktail (Roche Molecular Systems, Pleasanton, CA, USA). 
Homogenate was spun 100,000 g × 1 h, and the supernatant was saved as the soluble 
fraction for Aβ quantification. Aβ40 and Aβ42 Human ELISA kits (Invitrogen
TM 
Corporation, Camarillo, CA, USA) were used to quantify the levels of Aβ40 and Aβ42 
peptides in the brain soluble fractions. Quantitative determination was carried out 




total amount of protein from each individual sample (BCA method, Thermo Fisher 
Scientific, Wilmington, DE, USA). The number of APP/PS1 mice analyzed for each 
genotype (CB1 +/+, CB1 +/-, CB1 -/-) and age (<2, 3 and 6 months) was n = 5-6. 
2.6. Gel electrophoresis and western blotting 
Brain samples of mice aging 3 months were homogenized in RIPA lysis buffer (50mM 
Tris/HCl buffer, pH 7.4 containing 2mM EDTA, 0.2% Nonidet P-40, 1mM PMSF, 
protease, and phosphatase inhibitor cocktails, Roche Molecular Systems, USA). The 
homogenates were centrifuged for 15 min at 13,000 rpm. Protein concentration was 
determined with the BCA method (Thermo Scientific). Equal amounts of protein (20 μg) 
for each sample were loaded and separated by electrophoresis on sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) (10%) gels and transferred onto 
nitrocellulose membranes (Amersham, Freiburg, Germany). Non-specific bindings were 
blocked by incubation in 3% albumin in PBS containing 0.2% Tween for 1 h at room 
temperature. After washing, membranes were incubated overnight at 4°C with the 
antibodies against postsynaptic density protein-95 (PSD-95) (1:500, Invitrogen) and 
synaptophysin (1:4,000, Novocastra). Protein loading was monitored using an antibody 
against β-actin (1:10,000, Abcam). Membranes were then incubated for 1 h in the 
appropriate HRP- conjugated secondary antibody (1:2,000, Dako), and 
immunocomplexes were revealed by chemiluminescence reagent (ECL, Amersham). 
Densitometric quantification was carried out with TotalLab v2.01 software (Pharmacia, 
Sweden). Bands were normalized to β-actin. Six animals per genotype were analyzed. 
2.7. Statistical analysis 
Statistical analysis was performed with the SPSS® Statistics v21.0 software (IBM, New 
York, NY, USA). The frequency of observed genotypes was analyzed with Pearson’s chi-




performance, PV+ cells quantification and PSD-95 levels were analyzed with two-way 
ANOVA with APP/PS1 transgene and CB1 mutation as between factors, followed by 
Tukey’s post hoc when required. Aß quantifications were analyzed with a Student t-test. 





3.1 Reduced survival of APP/PS1 deficient for CB1 receptors  
As shown in Fig. 1A, crossing APP/PS1/CB1 +/- males with WT/CB1 +/- females resulted 
in the generation of pups bearing six different genotypes. The Pearson’s chi-squared test 
revealed that observed frequencies of each genotype were significantly different (2(2) = 
26.71, p < 0.001) from the expected frequencies according to Mendelian laws (50% WT 
and 50% APP/PS1, and for each one of these genotypes 25% CB1 +/+, 50% CB1 +/- and 
25% CB1 -/-). Specifically, the number of APP/PS1 knockout for CB1 receptor was 
drastically reduced at postnatal day 21, when the tail clips were collected for DNA 
isolation and genotyping. In contrast, the observed frequencies of each genotype were not 
significantly modified from the expected ones when analyzed in pups at embryonic day 
13.5 (78 pups analyzed, data not shown), suggesting that CB1 deficiency does not affect 
embryonic implantation or early development (before embryonic day 13.5) in APP/PS1 
mice. Most importantly, none of the APP/PS1/CB1 -/- mice survived more than two 
months, in spite they exhibited a healthy appearance and no external physical 
abnormalities. In at least three cases, during the daily handling of the animals, the 
researchers witnessed the sudden death of the APP/PS1/CB1 -/- mice at their home cage 
following spontaneous seizures. Kaplan-Meier test applied to the survival curve 
calculated up to six months of age (without considering those animals sacrificed at 7 
weeks or 3 months of age for brain samples collection) revealed a significant increase in 
the mortality of CB1 mutant mice bearing the APP/PS1 transgene compared to WT mice 
(2(5) = 257.21, p < 0.001; Fig. 1B). It is noticeable that the survival of APP/PS1/CB1 +/- 
mice and WT/CB1 -/- mice was also significantly reduced when compared to control 
animals at six months of age.  




Because of the serendipitous observation of the sudden death of a few APP/PS1/CB1 -/- 
mice after spontaneous seizures, we hypothesized that the increased mortality of these 
mutant mice could be related to an imbalance in the excitatory/inhibitory 
neurotransmission in brain areas such as hippocampus, which is closely related to the 
occurrence of seizures.  We observed that the genetic deletion of CB1 receptors reduced 
the density of PV+ inhibitory neurons in the hippocampus of APP/PS1 mice (Fig. 2A-C), 
as revealed two-way ANOVA (interaction between APP/PS1 and CB1 genotypes, F(1, 13) 
= 5.014, p < 0.05; no significant effect of APP/PS1 or CB1 genotypes) and subsequent 
post hoc test (p < 0.05 respect to WT/CB1 -/-). The reduction in the density of neurons 
was specific for inhibitory PV+ cells since no differences were observed in the total 
number of neurons in the hippocampus, as revealed the NeuN immunostaining 
quantification (data not shown). No significant modifications in PV+ cells density were 
observed in APP/PS1/CB1 +/- mice at 3 or 6 months, in spite of a tendency to decrease at 
6 months when compared to APP/PS1/CB1 +/+ animals (data not shown). Importantly, 
the decreased density of inhibitory neurons was not related with an increment of Aβ 
peptide production in APP/PS1/CB1 -/-. Thus, the levels of soluble Aβ peptide were not 
modified in mutant mice (Fig. 2D) and no Aβ plaques were observed in APP/PS1/CB1 -
/- mice at 7 weeks of age (data not shown). 
3.3. CB1 reduced expression accelerates the memory impairment associated to 
APP/PS1 transgene 
In order to evaluate a potential contribution of CB1 receptor deficiency to the progression 
of the AD-related cognitive impairment in APP/PS1 mice, and considering the 
impossibility to test CB1 -/- mice due to their premature mortality, memory performance 
was assessed at 3 (pre-symptomatic phase in APP/PS1 mice) and 6 (early symptomatic 




at 6 months of age APP/PS1 mice exhibited an evident memory impairment (Fig. 3B). 
Thus, two-way ANOVA revealed a significant effect of the APP/PS1 transgene (F(1, 37) = 
35.772, p < 0.001), CB1 deficiency (F(2, 37) = 4.571, p < 0.05) but no interaction between 
the two genotypes. Subsequent Tukey’s post hoc test revealed memory impairment in 
APP/PS1/CB1 +/+ (p < 0.001 respect to WT/CB1 +/+), APP/PS1/CB1 +/- (p < 0.001 
respect to WT/CB1 +/-) and WT/CB1 -/- (p < 0.05 respect to WT/CB1 +/+ and p < 0.01 
respect to WT/CB1 +/-). However, in spite that APP/PS1 mice at 3 months do not exhibit 
memory impairment normally, a significant memory deficit was observed in 
APP/PS1/CB1 +/-, indicating an acceleration of the cognitive impairment when CB1 
activity is reduced (Fig. 3A). Specifically, two-way ANOVA revealed a significant effect 
of the APP/PS1 transgene (F(1, 46) = 5.672, p < 0.05), but no CB1 genotype effect or 
interaction between the two factors at 3 months of age. Subsequent Tukey’s post hoc test 
revealed a reduction in the recognition index in APP/PS1/CB1 +/- when compared to 
APP/PS1/CB1 +/+ (p < 0.05) and to WT/CB1 +/- (p < 0.05). 
3.4. Reduction of CB1 expression does not alter Aβ processing but modifies synaptic 
composition in APP/PS1 mice  
We evaluated next whether the acceleration in memory impairment could be related to a 
modification in the Aβ processing, since Aβ peptide is known to induce cognitive 
disturbances in APP/PS1 mice. However, no significant difference was observed between 
the cortical Aβ burden (Fig. 4A-B) or soluble Aβ contents neither at 3 (data not shown) 
or 6 months of age in APP/PS1/CB1 +/- mice (Fig. 4C). These findings suggest that 
memory impairment in APP/PS1/CB1 +/- could be related to enhanced negative 
consequences of Aβ production rather than to an increase in Aβ levels. We next evaluated 
the levels of postsynaptic density protein-95 (PSD-95) and the presynaptic protein 




4D, APP/PS1/CB1 +/- exhibited at 3 months of age a significant reduction in the PSD-95 
contents when compared to WT/CB1 +/- (p < 0.05). No modifications in the levels of 






A number of previous reports suggested that targeting the CB1 receptor during the early 
stages could offer a strategy against AD, based on the neuroprotective effects against Aβ 
toxicity observed in certain experimental models after treatment with CB1 receptor 
agonists (Noonan et al, 2010; Chen et al, 2011; Aso et al, 2012; Haghani et al, 2012; 
Janefjord et al, 2014; Aso et al, 2015). The present study aimed to further explore the 
specific contribution of CB1 receptors to the progression of the cognitive impairment and 
the aberrant Aβ production typically occurring in AD by using APP/PS1 transgenic mice 
as an animal model of the disease. 
We generated a new mouse strain by crossing APP/PS1 transgenic mice with CB1 
knockout mice. Intriguingly, the observed frequency of APP/PS1 mice lacking the CB1 
receptor at postnatal day 21 was significantly reduced respect the expected frequency 
according to Mendelian laws, in spite that CB1 deficiency does not affect embryonic 
implantation or early development of transgenic animals, as revealed the genotyping of 
mice at embryonic day 13.5. These results indicate that a significant number of 
APP/PS1/CB1 -/- mice died during late intrauterine life or shortly after birth. Most 
importantly, none of the APP/PS1 mice mutant for CB1 receptor survived more than two 
months, revealing a major role for CB1 receptor in the viability of these transgenic mice. 
The mechanisms underlying the increased mortality of APP/PS1 mice lacking CB1 
receptor remain to be fully elucidated. However, based on the serendipitous observation 
of the premature death of a few APP/PS1/CB1 -/- mice after spontaneous seizures, we 
hypothesized that deficiency in CB1 receptor could lead to an imbalance in the 
excitatory/inhibitory neurotransmission leading to enhanced excitability in response to 
Aβ peptide production that might ultimately cause lethal seizures. Our hypothesis is based 




associated to Aβ peptide overproduction (Palop et al, 2007; Irizarry et al, 2012), which is 
increased with the progression of the disease (Amatniek et al, 2006; Cloyd et al, 2006) 
and (ii) the key role played by CB1 receptor in the control of neuronal excitability and 
epileptiform seizures (Lutz, 2004; Monory et al, 2006). In agreement with this hypothesis, 
we observed in APP/PS1/CB1 -/- mice at 7 weeks of age a decrease in the density of 
GABAergic inhibitory PV+ cells in the hippocampus. GABAergic function is enhanced 
in this brain region in certain AD models and likely serves to counteract Aβ-induced 
neuronal overexcitation (Palop et al, 2007). Thus, the deficiency in the inhibitory 
mechanisms suggested by the decrease in PV+ cells density in APP/PS1/CB1 -/- mice, 
together with the already known role of CB1 receptors on hippocampal glutamatergic 
neurons on providing on-demand endocannabinoid-dependent protection against 
excitotoxic seizures (Monory et al, 2006), could account for an aberrant hyperexcitability 
and the consequent incidence of life-threatening seizures in these APP/PS1 mice lacking 
CB1 receptors. The specific loss of PV
+ cells in APP/PS1/CB1 -/- mice could be related 
with the increased susceptibility to Aβ toxicity of GABAergic interneurons already 
reported both in patients and APP/PS1 mice (Davies et al 1980, Ramos et al 2006, 
Takahashi et al 2010, Verret et al 2012). Neither the soluble levels of Aβ40 or Aβ42, the 
most toxic form of this peptide, were altered in APP/PS1/CB1 -/- mice, suggesting that 
CB1 deficiency impaired the mechanisms of defense against Aβ detrimental effects rather 
than the production of this peptide. 
Considering the impossibility to characterize the progressive cognitive impairment of 
APP/PS1/CB1 -/- mice due to their premature death, we evaluated memory performance 
of APP/PS1 mice expressing reduced levels of CB1 receptor (APP/PS1/CB1 +/-) at 3 and 
6 months of age, corresponding respectively to the pre-symptomatic and to the early 




resulted in the acceleration of the memory impairment usually evidenced by APP/PS1 
from 6 months of age, since APP/PS1/CB1 +/- exhibited a significant reduction in the 
recognition index in the two-object recognition test at 3 months of age. This finding 
agrees with previous reports demonstrating that APP23 transgenic mice deficient for CB1 
receptor presented enhanced cognitive deficits (Stumm et al, 2013). WT/CB1 -/- also 
exhibited a memory deficit at 6 months of age, in accordance with previous reports 
demonstrating an accelerated age-related decline in cognitive functions in the absence of 
CB1 receptors (Bilkei-Gorzo et al, 2005). Neither the levels of soluble Aβ peptide or Aβ 
deposition were affected by the reduced CB1 receptor expression in APP/PS1/CB1 +/- 
mice, supporting our assumption about a major role for CB1 receptor in the defense 
against Aβ detrimental effects rather than in the production of this peptide. However, 
Stumm et al (2013) revealed that APP23 transgenic mice knockout for CB1 receptor 
exhibited reduced APP protein levels and Aβ plaque deposition and a recent report 
demonstrated that APP is able to alter membrane localization and inhibitory signalling 
activity of CB1 receptor in the hippocampus of Tg2576 mice (Maccarrone et al, 2018). 
Thus, a direct or indirect participation of CB1 receptor in Aβ processing cannot be 
completely ruled out. 
Aβ peptide is known to induce synaptic dysfunction during early stages of AD by 
deregulating molecular organization of the postsynaptic density (Liu et al, 2010; Oyelami 
et al, 2016). Because of this, we evaluated the levels of PSD-95, one of the major 
scaffolding protein in the excitatory postsynaptic density and a potent regulator of 
synaptic strength (Chen et al, 2011b), and the levels of the presynaptic component 
synaptophysin, which are known to be reduced in APP/PS1 mice at advanced stages of 
the neurodegenerative process (Woo et al, 2015; Mitew et al, 2013). Interestingly, 




levels, a significant reduction in the PSD-95 contents but no modifications of the 
synaptophysin levels. PSD-95 protein has been previously demonstrated to play a key 
role in the retrograde synaptic signaling elicited by CB1 receptor to regulate the activity-
dependent inhibition of synaptic strength in the brain (Chen et al, 2011c). Thus, PSD-95 
reduction could lead to an alteration of the synaptic dynamics that could ultimately 
account for the accelerated cognitive impairment observed in APP/PS1/CB1 +/- animals.   
In summary, the present study reveals that CB1 receptor blockade reduces the life 
expectancy of APP/PS1 mice and accelerates their cognitive impairment, suggesting a 
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Figure 1: A. Distribution of the six possible genotypes in the offspring from mating of 
APP/PS1/CB1 heterozygous males (+/-) and WT/CB1 +/- females at postnatal day 21. The 
observed genotype frequencies were significantly different from the expected frequencies 
according to the Mendelian laws, mainly due to the drastic reduction in the number of 
APP/PS1/CB1 -/- mice. N: total number of mice studied. B. Survival curve calculated up 
to six months of age revealed none of the APP/PS1/CB1 -/- mice survived more than two 
months from birth. The viability of APP/PS1/CB1 +/- mice and WT/CB1 -/- mice was also 
significantly reduced when compared to control animals at six months of age. 
Figure 2: Reduction of the density of PV+ inhibitory neurons in the hippocampus of 
APP/PS1/CB1 -/- at 7 weeks of age. A. Low magnification images showing representative 
hippocampal sections stained with a specific antibody against PV. Scale bar represents 
500 m. B. Higher magnification of brain areas indicated by black squares. Scale bar 
represents 100 m. C. Quantification of PV+ density in the hippocampus based on 3 
pictures from each animal and 5-6 animals per group. D.  No significant effect of genotype 
was observed in the levels of cortical soluble Aβ40 or Aβ42 peptide at 7 weeks of age (n = 
5-6 per genotype). Data are expressed as the mean values ± SEM. * p < 0.05 compared 
to WT/CB1 -/-. 
Figure 3: CB1 reduced expression accelerates memory impairment in APP/PS1 mice. A. 
Memory performance of animals aged 3 months (pre-symptomatic phase in APP/PS1 
mice) in the two-object recognition test was significantly reduced in APP/PS1/CB1 +/- 
when compared to APP/PS1/CB1 +/+ or WT/CB1 +/- mice. B. At 6 months of age (early 
symptomatic phase), all the APP/PS1 animals, independently of CB1 genotype, exhibited 
memory impairment in the two-object recognition test. Moreover, WT/CB1 -/- also 
showed a decrease in the recognition index. Data are expressed as the mean values ± SEM 




the same genotype for CB1 receptor. # p < 0.05 compared to APP/PS1/CB1 +/+. $ p < 
0.05 compared to WT/CB1 +/+. $ p 0.01 compared to WT/CB1 +/-. N.A.: Not Applicable.  
Figure 4: A. Representative images of Aβ specific immunostaining in cortical sections 
of APP/PS1/CB1 +/+ (left) and APP/PS1/CB1 +/- (right) mice at 3 (upper) and 6 (bottom) 
months of age. Arrow heads indicate Aβ plaques. Scale bar represents 200 m. B. Aβ 
burden quantification in cortical sections reveals no alteration in the Aβ deposition in 
APP/PS1/CB1 +/- mice (black bars) compared to APP/PS1/CB1 +/+ littermates (open 
bars) at 3 or 6 months of age (n = 5-10 animals per genotype). C. Neither the soluble Aβ40 
or Aβ42 levels of APP/PS1/CB1 +/- mice (black bars) were significantly modified respect 
APP/PS1/CB1 +/+ littermates (open bars) in cortical homogenates from animals ageing 6 
months (n = 5-6 animals per genotype). D. Upper: Representative immunoblots for PSD-
95 and corresponding -actin loading control. Bottom: Quantification of the PSD-95 
levels in brain homogenates of animals ageing 3 months revealed a significant reduction 
in APP/PS1/CB1 +/- when compared to WT/CB1 +/- mice (n = 6 animals per genotype). 
E. Upper: Representative immunoblots for synaptophysin and corresponding -actin 
loading control. Bottom: Quantification of the synaptophysin levels in brain homogenates 
of animals ageing 3 months revealed no significant alterations due to genotype (n = 6 
animals per group). Data are expressed as mean values ± SEM. * p < 0.05 compared to 
WT/CB1 +/-. 
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